| Literature DB >> 24067392 |
Anitra C Carr1, Stephanie M Bozonet, Juliet M Pullar, Jeremy W Simcock, Margreet C M Vissers.
Abstract
Whether vitamin C from wholefoods has equivalent bioavailability to a purified supplement remains unclear. We have previously showed that kiwifruit provided significantly higher serum and tissue ascorbate levels than synthetic vitamin C in a genetically vitamin C-deficient mouse model, suggesting a synergistic activity of the whole fruit. To determine if these results are translatable to humans, we carried out a randomized human study comparing the bioavailability of vitamin C from kiwifruit with that of a vitamin C tablet of equivalent dosage. Thirty-six young non-smoking adult males were randomized to receive either half a gold kiwifruit (Actinidia Chinensis var. Hort 16A) per day or a comparable vitamin C dose (50 mg) in a chewable tablet for six weeks. Ascorbate was monitored weekly in fasting venous blood and in urine, semen, leukocytes, and skeletal muscle (vastus lateralis) pre- and post-intervention. Dietary intake of vitamin C was monitored using seven day food and beverage records. Participant ascorbate levels increased in plasma (P < 0.001), urine (P < 0.05), mononuclear cells (P < 0.01), neutrophils (P < 0.01) and muscle tissue (P < 0.001) post intervention. There were no significant differences in vitamin C bioavailability between the two intervention groups in any of the fluid, cell or tissue samples tested. Overall, our study showed comparable bioavailability of synthetic and kiwifruit-derived vitamin C.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24067392 PMCID: PMC3798928 DOI: 10.3390/nu5093684
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Parallel groups study design. * Weekly plasma samples; ** urine, semen and leukocyte samples; *** urine, semen, leukocyte and skeletal muscle samples.
Characteristics of individuals screened and enrolled in the study.
| Screened a | Vitamin C Group a | Kiwifruit Group a | |
|---|---|---|---|
| Age (years) | 21 ± 3 | 21 ± 3 | 22 ± 4 |
| Weight (kg) | 81 ± 16 | 84 ± 19 | 89 ± 23 |
| Height (cm) | 182 ± 7 | 181 ± 7 | 181 ± 7 |
| BMI (kg/m2) | 24 ± 4 | 26 ± 5 | 27 ± 6 * |
| Ascorbate (µmol/L) | 48 ± 16 | 31 ± 11 ** | 34 ± 10 ** |
a Data represent mean ± SD; * P < 0.05, ** P < 0.001 for unpaired t-test of intervention groups versus screened group. There were no significant differences between the intervention groups.
Change in vitamin C intake and ascorbate concentration in body fluids, cells and tissue following supplementation with 50 mg vitamin C or half a kiwifruit per day for six weeks.
| Vitamin C group a (50 mg/day) | Kiwifruit group a (half/day) | Between group | |||||
|---|---|---|---|---|---|---|---|
| 31.2 ± 3.1 | 76.7 ± 2.6 *** | 29.1 ± 2.9 | 28.6 ± 3.1 | 73.4 ± 4.2 *** | 31.4 ± 5.1 | 0.512 | |
| Plasma (µmol/L) | 23.5 ± 2.5 | 51.3 ± 3.5 *** | 34.3 ± 4.4 * | 22.7 ± 2.5 | 45.5 ± 2.5 *** | 30.5 ± 3.1 | 0.860 |
| Urine (µmol/24 h) | 42.8 ± 9.2 | 104.2 ± 27.6 * | 59.5 ± 19.9 | 32.3 ± 8.1 | 70.5 ± 17.0 * | 64.7 ± 29.8 | 0.503 |
| Semen (µmol/L) | 284.8 ±27.0 | 321.0 ± 33.3 | 264.4 ± 31.1 * | 326.3 ± 47.5 | 378.8 ± 42.7 | 237.7 ± 19.6 * | 0.676 |
| Mononuclear cells (nmol/108 cells) | 38.7 ± 6.2 | 84.5 ± 6.3 *** | 78.5 ± 4.3 ** | 60.5 ± 6.1 | 90.9 ± 6.1 ** | 75.2 ± 5.2 | 0.227 |
| Neutrophils (nmol/108 cells) | 21.9 ± 3.1 | 39.6 ± 3.8 ** | 24.9 ± 2.1 | 13.7 ± 2.4 | 30.4 ± 2.5 *** | 24.8 ± 1.7 *** | 0.798 |
| Skeletal muscle (nmol/g) | 14.5 ± 2.0 | 61.3 ± 3.5 *** | nd | 15.1 ± 2.5 | 52.8 ± 5.0 *** | nd | 0.429 |
a Data represent mean ± SEM; b P values were determined by unpaired t-test of vitamin C group versus kiwifruit group post-intervention following subtraction of baseline values; * P < 0.05 and ** P < 0.01 and *** P < 0.001 for paired t-test of intervention versus baseline. nd = not determined.
Figure 2Plasma ascorbate concentrations in vitamin C group (50 mg/day, ●) and kiwifruit group (0.5/day, ○). Data represent mean ± SEM. Two way analysis of variance with Fisher pairwise multiple comparison procedure indicated a significant increase in plasma ascorbate from one week post-intervention (week 6) onwards, but no significant difference between the two interventions.